MADISON, NJ–(BUSINESS WIRE)–Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Rahway, NJ, USA (NYSE: MRK), has announced today that it has signed a definitive agreement whereby Merck Santé Animale will acquire Vence from its founders and shareholders. Vence is an innovator in virtual fencing for rotational grazing and livestock management. The acquisition is expected to close in the third quarter of 2022, subject to customary closing conditions. Specific terms of the agreement were not disclosed.
Vence, a private company, provides enhanced technology to producers and ranchers to track, monitor and manage the movement of livestock through a high-tech platform of virtual fencing solutions. Using a computer or smartphone, customers have the ability to manage livestock movements and facilitate rotational grazing. Vence’s virtual fencing technology can reduce the need for fencing to subdivide pastures and allows producers and ranchers to manage their livestock and grass inventory, while reducing labor and material costs. fencing.
“The acquisition of Vence will expand our portfolio with complementary products and technologies to advance animal health and welfare and outcomes for our customers,” said Rick DeLuca, President of Merck Animal Health. “Vence fits naturally into Merck Santé Animale’s growing portfolio of animal intelligence products, which includes identification, traceability and surveillance products. This new technology will give cow-calf producers the ability to track their cattle and move them from pasture to pasture.
“I believe Merck Animal Health is the best long-term home for this technology and our team. Their unparalleled animal husbandry expertise, ability to develop and scale hardware products, high quality customer support, and a strong global footprint to expand Vence’s market reach makes us truly excited to join Merck Animal Health,” said Frank Wooten, Founder and CEO. , Vence.
Vence technology is currently available in the United States and parts of Australia.
Vence was founded to improve the accessibility and availability of sustainably raised animal protein. We contribute to more sustainable animal production by enabling producers to better manage their herds, make better use of their land resources and ultimately improve the production of more than 20% of the protein consumed worldwide. To realize our vision, we use connected sensors, artificial intelligence and cutting-edge animal behavioral research to help innovate one of society’s oldest and most valuable industries.
About Merck Animal Health
At Merck, known as MSD outside the United States and Canada, we are united around our purpose: We use the power of cutting-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, delivering innovative medicines, vaccines and healthcare solutions for the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Rahway, NJ, USA, is the global animal health business of Merck. Through its commitment to health science Animals®, Merck Animal Health offers veterinarians, breeders, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services, as well as a comprehensive suite of connected technologies including identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, welfare and performance of animals and the people who care for them. It invests heavily in dynamic and comprehensive R&D resources and a modern global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.
Merck & Co., Inc., Rahway, NJ, USA Forward-Looking Statement
This press release from Merck & Co., Inc., Rahway, NJ, USA (the “Company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. These statements are based on the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and around the world; global trends toward health care cost containment; technological advances, new products and patents obtained by competitors; challenges inherent in developing new products, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and exposure to litigation, including patent litigation, and/or regulatory actions.
The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Other factors that could cause results to differ materially from those described in the forward-looking statements can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and other company filings. with the Securities and Exchange Commission. (SEC) available on the SEC’s website (www.sec.gov).